The estimated Net Worth of Donald E Jr Morel is at least $8.99 Milión dollars as of 15 May 2019. Donald Morel owns over 10,000 units of Catalent stock worth over $2,800,106 and over the last 19 years he sold CTLT stock worth over $5,893,500. In addition, he makes $294,975 as Independent Director at Catalent.
Donald has made over 16 trades of the Catalent stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of CTLT stock worth $444,400 on 15 May 2019.
The largest trade he's ever made was exercising 197,401 units of Catalent stock on 23 May 2013 worth over $8,547,463. On average, Donald trades about 5,032 units every 16 days since 2005. As of 15 May 2019 he still owns at least 46,958 units of Catalent stock.
You can see the complete history of Donald Morel stock trades at the bottom of the page.
Dr. Donald E. Morel Jr. Ph.D. is Independent Director of the Company. Dr. Morel retired in June 2015 as Chairman of West Pharmaceutical Services, Inc. (“West”), a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, a position he had held since March 2003. He also served as West’s Chief Executive Officer from April 2002 until April 2015 and as its President from April 2002 until June 2005. Currently, Dr. Morel serves as Chairman of the Board of Directors of the American Oncologic Hospital of the Fox Chase Cancer Center. He also serves as a Chairman of the Board of Trustees of the Franklin Institute and is a Trustee of Lafayette College. Additionally, Dr. Morel has been a director of Stevanato Group since September 2018 and of Integra Life Sciences Holdings Corporation since August 2013. Prior to that, he served as a director of Kensey Nash Corporation from 2010 until 2012. Dr. Morel obtained a Master of Science degree and a Ph.D. in Materials Science from Cornell University and a Bachelor of Science degree in Engineering from Lafayette College.
As the Independent Director of Catalent, the total compensation of Donald Morel at Catalent is $294,975. There are 13 executives at Catalent getting paid more, with John Chiminski having the highest compensation of $8,514,990.
Donald Morel is 62, he's been the Independent Director of Catalent since 2015. There are 5 older and 22 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
Donald's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius a Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: